AngioSoma, Inc. Announces a Liprostin™ Focused Joint Venture

MONTGOMERY, Texas–(BUSINESS WIRE)–AngioSoma, Inc. (OTCQB:SOAN) announces a joint venture with La Jolla Capital Partners LLC (‘La Jolla’) focused on the funding and management of US Food and Drug Administration (‘FDA’) Liprostin™ Phase III trials, as well as the licensing of Liprostin™ worldwide thereafter. Liprostin™ is a liposomal encapsulated prostaglandin e1 (‘PGE1’) and is AngioSoma, Inc.’s Read more about AngioSoma, Inc. Announces a Liprostin™ Focused Joint Venture[…]